HBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harvard Bioscience Inc (HBIO) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is weak, with declining revenue, net income, and EPS. Additionally, there are no significant positive trading trends, news catalysts, or strong trading signals to suggest an immediate buying opportunity. While the technical indicators show some bullish signs, the overall sentiment and fundamentals do not align with a strong buy recommendation.
The MACD histogram is positive (0.00218) but contracting, indicating a lack of strong momentum. RSI is neutral at 43.927, suggesting no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is near its support level (S1: 0.562). However, the pre-market price is slightly down (-0.18%), and the stock shows limited short-term upside potential.
The stock has a 70% chance to increase by 2.34% in the next week and 5.99% in the next month. Gross margin has improved YoY to 54.23%, up 4.23%.
No recent news, insider trading, hedge fund activity, or congress trading data to indicate positive sentiment. The pre-market price is slightly down (-0.18%), and the stock has no strong trading signals.
In Q3 2025, revenue dropped by -6.27% YoY to $20.59M. Net income fell by -74.36% YoY to -$1.23M, and EPS declined by -72.73% YoY to -0.03. However, gross margin improved by 4.23% YoY to 54.23%.
No recent analyst rating or price target changes available.
